five

Supplementary file 1_Prevalence and influencing factors of insomnia in patients with coronary heart disease: a systematic review and meta-analysis.docx

收藏
NIAID Data Ecosystem2026-05-10 收录
下载链接:
https://figshare.com/articles/dataset/Supplementary_file_1_Prevalence_and_influencing_factors_of_insomnia_in_patients_with_coronary_heart_disease_a_systematic_review_and_meta-analysis_docx/31909948
下载链接
链接失效反馈
官方服务:
资源简介:
BackgroundSleep is a pivotal component of cardiovascular health. However, clinical efforts in coronary heart disease (CHD) disproportionately focus on sleep-disordered breathing, while insomnia, the most prevalent sleep disorder among adults, remains underdiagnosed and undertreated. AimsThis meta-analysis systematically evaluates the prevalence of insomnia and its influencing factors in patients with CHD to inform clinical prevention and management strategies. MethodsTen databases were searched from inception to 7 September 2025. The prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) were extracted to evaluate the prevalence of insomnia and its influencing factors in patients with CHD. RevMan 5.4 and Stata 15.0 software was used for data processing. Subgroup analyses, meta-regression, and sensitivity analyses were performed. ResultsNineteen studies involving 5928 patients with CHD were included. The overall pooled prevalence of insomnia was 51.8% (95% CI: 0.446–0.590, P < 0.001). Significant risk factors identified were female sex(OR = 2.00, 95% CI: 1.58–2.52, P < 0.001), anxiety (OR = 1.61, 95% CI: 1.36–1.91, P < 0.001), depression (OR = 2.15, 95% CI: 1.48–3.13, P < 0.001), CHD duration ≥3 years (OR = 1.73, 95% CI: 1.25–2.40, P = 0.001), diabetes (OR = 1.50, 95% CI: 1.45–1.56, P < 0.001), and gastritis (OR = 2.24, 95% CI: 1.62–3.11, P < 0.001). Conclusioninsomnia has a substantial prevalence in patients with CHD. Clinicians should prioritize early identification and intervention targeting modifiable risk factors (anxiety, depression, diabetes, and gastritis), particularly in female patients and those with a CHD duration ≥3 years. Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024617785.
创建时间:
2026-04-01
二维码
社区交流群
二维码
科研交流群
商业服务